Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in toxicity (adverse events probably due to drug) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
1 finding from 1 review
Oral candidiasis (present) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… led to lower oral candidiasis (present) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Toxicity (adverse events probably due to drug) · Patients with cancer receiving chemotherapy and/or radiotherapy
Antifungal drugs absorbed from GI tract showed no clear difference in toxicity (adverse events probably due to drug) compared with antifungal drugs not absorbed from GI tract; GRADE not reported.
1 finding from 1 review
Time to death from prostate cancerMedian · clinically localized and locally advanced prostate cancer
Dose‐escalated RT showed no clear difference in time to death from prostate cancer compared with conventional dose RT (moderate certainty).
1 finding from 1 review
Severe RT toxicity (grade ≥ 3) · clinically localized and locally advanced prostate cancer
Dose‐escalated RT probably leads to higher severe RT toxicity (grade ≥ 3) compared with conventional dose RT (moderate certainty).
1 finding from 1 review
Time to death from any cause · clinically localized and locally advanced prostate cancer
Dose‐escalated RT showed no clear difference in time to death from any cause compared with conventional dose RT (moderate certainty).
1 finding from 1 review
Time to distant metastasis · clinically localized and locally advanced prostate cancer
Dose‐escalated RT showed no clear difference in time to distant metastasis compared with conventional dose RT (moderate certainty).
1 finding from 1 review
Overall RT toxicity (grade ≥ 1) · clinically localized and locally advanced prostate cancer
Dose‐escalated RT may leads to higher overall RT toxicity (grade ≥ 1) compared with conventional dose RT (low certainty).
1 finding from 1 review
Quality of life · clinically localized and locally advanced prostate cancer
1 finding from 1 review
Survival ‐ · adults (aged 18+) with colorectal cancer
Adjunctive Coriolus versicolor may leads to higher survival ‐ compared with no adjunctive treatment (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes withdrawal from treatment due to adverse events ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Adverse events: Oral cavity disorders (includes oral dryness and mucositis)‐ · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Oral cavity disorders (includes oral dryness and… compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Adverse events: nausea · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Nausea ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Diarrhoea · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Diarrhoea ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Adverse events: Neutrophils decreased ‐ · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Neutrophils decreased ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Adverse effect: fatigue · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Fatigue ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Local recurrence‐free survival · health problem or population
Summary of Findings Table ‐ PBI?APBI probably leads to higher local recurrence‐free survival ‐ total (LR‐FS) compared with WBRT (moderate certainty).
1 finding from 1 review
Cosmesis · health problem or population
Summary of Findings Table ‐ PBI?APBI probably leads to higher cosmesis, physician/nurse‐reported compared with WBRT (moderate certainty).
1 finding from 1 review
Overall survival · health problem or population
Summary of Findings Table ‐ PBI?APBI showed no clear difference in overall survival compared with WBRT (high certainty).
1 finding from 1 review